Enliven Therapeutics (ELVN) Shares Issued (2020 - 2026)

Enliven Therapeutics has disclosed Shares Issued across 7 years of filings, most recently posting $10.1 million for Q1 2026.

• Shares Issued for Q1 2026 came in at $10.1 million, up 4196.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.1 million (up 236.97% YoY), and the FY2025 annual result was $2.3 million, down 36.79% from the prior year.
• Shares Issued came in at $10.1 million for Q1 2026 at Enliven Therapeutics, up from $528000.0 in the prior quarter.
• In the past five years, Shares Issued ranged from a high of $162.9 million in Q1 2023 to a low of -$161.1 million in Q3 2023.
• The 5-year median for Shares Issued is $453000.0 (2024), against an average of $998176.5.
• Peak annual rise in Shares Issued reached 28329.32% in 2023, while the deepest fall reached 30800.0% in 2023.
• Enliven Therapeutics' Shares Issued stood at $591000.0 in 2022, then tumbled by 84.77% to $90000.0 in 2023, then surged by 403.33% to $453000.0 in 2024, then increased by 16.56% to $528000.0 in 2025, then surged by 1803.98% to $10.1 million in 2026.
• The last three Shares Issued figures came in at $10.1 million (Q1 2026), $528000.0 (Q4 2025), and $209000.0 (Q3 2025), per Business Quant data.